Display options
Cite
He Y, Zhang Y, Jin C, et al. Impact of XRCC2 Arg188His polymorphism on cancer susceptibility: a meta-analysis. PLoS One. 2014;9(3):e91202doi: 10.1371/journal.pone.0091202.
He, Y., Zhang, Y., Jin, C., Deng, X., Wei, M., Wu, Q., Yang, T., Zhou, Y., & Wang, Z. (2014). Impact of XRCC2 Arg188His polymorphism on cancer susceptibility: a meta-analysis. PloS one, 9(3), e91202. https://doi.org/10.1371/journal.pone.0091202
He, Yazhou, et al. "Impact of XRCC2 Arg188His polymorphism on cancer susceptibility: a meta-analysis." PloS one vol. 9,3 (2014): e91202. doi: https://doi.org/10.1371/journal.pone.0091202
He Y, Zhang Y, Jin C, Deng X, Wei M, Wu Q, Yang T, Zhou Y, Wang Z. Impact of XRCC2 Arg188His polymorphism on cancer susceptibility: a meta-analysis. PLoS One. 2014 Mar 12;9(3):e91202. doi: 10.1371/journal.pone.0091202. eCollection 2014. PMID: 24621646; PMCID: PMC3951328.
Copy Download .nbib Format: NLM
Share it on

PLoS One. 2014 Mar 12;9(3):e91202. doi: 10.1371/journal.pone.0091202. eCollection 2014.

Impact of XRCC2 Arg188His polymorphism on cancer susceptibility: a meta-analysis.

PloS one

Yazhou He, Yuanchuan Zhang, Chengwu Jin, Xiangbing Deng, Mingtian Wei, Qingbin Wu, Tinghan Yang, Yanhong Zhou, Ziqiang Wang

Affiliations

  1. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, P.R China; West China School of Medicine/West China Hospital, Sichuan University, Chengdu, Sichuan Province, P.R China.
  2. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, P.R China.
  3. West China School of Medicine/West China Hospital, Sichuan University, Chengdu, Sichuan Province, P.R China.
  4. Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu,Sichuan Province, P.R China.

PMID: 24621646 PMCID: PMC3951328 DOI: 10.1371/journal.pone.0091202

Abstract

BACKGROUND: Association between the single nucleotide polymorphism rs3218536 (known as Arg188His) located in the X-ray repair cross complementing group 2 (XRCC2) gene and cancer susceptibility has been widely investigated. However, results thus far have remained controversial. A meta-analysis was performed to identify the impact of this polymorphism on cancer susceptibility.

METHODS: PubMed and Embase databases were searched systematically until September 7, 2013 to obtain all the records evaluating the association between the XRCC2 Arg188His polymorphism and the risk of all types of cancers. We used the odds ratio (OR) as measure of effect, and pooled the data in a Mantel-Haenszel weighed random-effects meta-analysis to provide a summary estimate of the impact of this polymorphism on breast cancer, ovarian cancer and other cancers. All the analyses were carried out in STATA 12.0.

RESULTS: With 30868 cases and 38656 controls, a total of 45 case-control studies from 26 publications were eventually included in our meta-analysis. No significant association was observed between the XRCC2 Arg188His polymorphism and breast cancer susceptibility (dominant model: OR = 0.94, 95%CI = 0.86-1.04, P = 0.232). However, a significant impact of this polymorphism was detected on decreased ovarian cancer risk (dominant model: OR = 0.83, 95%CI = 0.73-0.95, P = 0.007). In addition, we found this polymorphism was associated with increased upper aerodigestive tract (UADT) cancer susceptibility (dominant model: OR = 1.51, 95%CI = 1.04-2.20, P = 0.032).

CONCLUSION: The Arg188His polymorphism might play different roles in carcinogenesis of various cancer types. Current evidence did not suggest that this polymorphism was directly associated with breast cancer susceptibility. However, this polymorphism might contribute to decreased gynecological cancer risk and increased UADT cancer risk. More preclinical and epidemiological studies were still imperative for further evaluation.

References

  1. PLoS One. 2013;8(2):e56797 - PubMed
  2. Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2476-84 - PubMed
  3. Nat Rev Mol Cell Biol. 2003 Jun;4(6):435-45 - PubMed
  4. Thyroid. 2009 Oct;19(10):1067-75 - PubMed
  5. Cancer. 2011 Sep 15;117(18):4312-24 - PubMed
  6. Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2557-65 - PubMed
  7. Cancer Treat Rev. 2012 Apr;38(2):89-100 - PubMed
  8. Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2326-34 - PubMed
  9. Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2569-78 - PubMed
  10. Arch Med Sci. 2012 Dec 20;8(6):1065-75 - PubMed
  11. Nat Genet. 2001 Mar;27(3):247-54 - PubMed
  12. Mutat Res. 2011 May 10;709-710:67-72 - PubMed
  13. Hum Genet. 2006 May;119(4):376-88 - PubMed
  14. Carcinogenesis. 2004 Feb;25(2):189-95 - PubMed
  15. DNA Repair (Amst). 2005 Sep 28;4(10):1068-74 - PubMed
  16. J Obstet Gynaecol Res. 2012 Jun;38(6):918-24 - PubMed
  17. Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):330-1 - PubMed
  18. Nat Cell Biol. 2000 Oct;2(10):757-61 - PubMed
  19. Eur J Gynaecol Oncol. 2012;33(2):145-50 - PubMed
  20. Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):319-23 - PubMed
  21. Neuro Oncol. 2010 Jan;12(1):37-48 - PubMed
  22. Breast Cancer Res Treat. 2010 Aug;123(1):219-25 - PubMed
  23. Mol Biol Rep. 2011 Apr;38(4):2849-54 - PubMed
  24. Carcinogenesis. 2006 Mar;27(3):560-7 - PubMed
  25. Int J Cancer. 2005 Nov 20;117(4):611-8 - PubMed
  26. Nature. 1998 Dec 17;396(6712):643-9 - PubMed
  27. J Natl Cancer Inst. 2006 Oct 4;98(19):1382-96 - PubMed
  28. Am J Gastroenterol. 2008 Feb;103(2):360-7 - PubMed
  29. Carcinogenesis. 2007 Aug;28(8):1788-93 - PubMed
  30. Pathol Oncol Res. 2013 Jul;19(3):553-8 - PubMed
  31. Semin Cell Dev Biol. 2011 Oct;22(8):898-905 - PubMed
  32. Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):1016-9 - PubMed
  33. PLoS One. 2013;8(3):e58170 - PubMed
  34. J Biol Chem. 2000 Sep 15;275(37):29100-6 - PubMed
  35. Biochem Biophys Res Commun. 2007 Jan 19;352(3):763-8 - PubMed
  36. Nature. 1999 Sep 23;401(6751):397-9 - PubMed
  37. Genet Mol Biol. 2012 Jan;35(1):32-7 - PubMed
  38. Cancer Res. 2004 May 1;64(9):3009-13 - PubMed
  39. Int J Cancer. 2004 Dec 10;112(5):901-4 - PubMed
  40. Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3081-9 - PubMed

Substances

MeSH terms

Publication Types